Form 4: Oramed Pharmaceuticals CEO Nadav Kidron Acquires 433,500 Shares Through Restricted Stock Units

Oramed Pharmaceuticals CEO Nadav Kidron acquired 433,500 shares of common stock through restricted stock units, increasing his total holdings to 2,259,598 shares.

Summary

• Nadav Kidron, the President and CEO of Oramed Pharmaceuticals, acquired 433,500 shares of common stock on January 2, 2025.
• These shares were acquired through Restricted Stock Units (RSUs) that will vest in quarterly installments over three years, starting January 1, 2025.
• The RSUs convert into common stock on a one-for-one basis.
• Following this transaction, Mr. Kidron's total direct holdings increased to 2,259,598 shares.
• Mr. Kidron also indirectly owns 126,000 shares through a wholly-owned corporation.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. There are no negative implications or surprises.

Positives

• The acquisition of shares by the CEO demonstrates confidence in the company's future.
• The vesting schedule of the RSUs aligns the CEO's interests with the long-term performance of the company.

Industry Context

This type of transaction is common for executive compensation, aligning management's interests with shareholders through equity ownership. It is a standard practice in publicly traded companies.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) for executive compensation is a common practice among publicly traded companies, particularly in the biotechnology and pharmaceutical sectors.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also use RSUs as part of their executive compensation packages.
• The vesting schedule of three years is also typical, ensuring long-term alignment between executive performance and shareholder value.

Stakeholder Impact

• The increased share ownership by the CEO may be viewed positively by shareholders, indicating confidence in the company's future performance.
• The vesting schedule of the RSUs aligns the CEO's interests with the long-term performance of the company, which is beneficial for shareholders.

Key Dates

Keywords

Oramed Pharmaceuticals, Nadav Kidron, Restricted Stock Units, RSUs, Share Acquisition, Insider Trading, Executive Compensation, Stock Ownership